Ethnic differences in responses to disease modifying drugs
نویسندگان
چکیده
منابع مشابه
Ethnic differences in responses to disease modifying drugs.
BACKGROUND AND OBJECTIVE The UK has a growing South Asian population. In the South Asian population of Bradford people appear to be less tolerant of disease-modifying anti-rheumatic drugs (DMARDs). One reason for this may be poor communication during patient education, which is generally designed for white North European people. Our objective was to obtain information on DMARDs that were used, ...
متن کاملEthnic differences in renal responses to furosemide.
Blacks have a greater tendency to retain Na than whites. The present study sought evidence for ethnic differences in parameters reflective of Na uptake by the Na,K,2Cl cotransporter in the thick ascending limb, namely, the urine concentration and urinary excretion of certain cations before and after furosemide administration (40 mg IV). Subjects were healthy (ages 18 to 36 years). During the pr...
متن کاملDisease-modifying drugs in Alzheimer’s disease
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memory loss. Once the disease progresses, patients experience difficulties in sense of direction, oral communication, calculation, ability to learn, and cognitive thinking. The median duration of the disease is 10 years. The pathol...
متن کاملBiologic Disease-Modifying Antirheumatic Drugs
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2003
ISSN: 1460-2172
DOI: 10.1093/rheumatology/keg354